



# News Release

## **NORGINE TO PRESENT AT UBS 2004 – GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE**

Norgine today announced that it will present at the UBS 2004 Global Specialty Pharmaceuticals Conference being held at the Grand Hyatt New York in New York City on 24 and 25 May 2004.

Peter Stein, Norgine's Chief Executive Officer, will provide an overview of the Company, discuss first quarter 2004 results, recent developments, and outline future opportunities. Mr. Stein's presentation will take place on Tuesday 25 May at 1600hrs Eastern Standard Time.

An audio webcast of Mr. Stein's presentation will be available via the UBS web site both live and by replay. To access the live audio webcast, go to [www.ibb.ubs.com](http://www.ibb.ubs.com). Find the Conferences icon in the middle of the page, click on the link and then follow the link for the webcast under the Global Specialty Pharmaceuticals Conference heading. Replay will begin 3 hours after the actual presentation time and will be available until 25 June 2004.

Norgine is a European specialty pharmaceutical company with a direct presence throughout Western Europe. The company revenues reached €133 million in 2003, an increase of 12%, the seventeenth consecutive year of double digit growth. Norgine's activities span from research and development through manufacturing to a sales and marketing team including over 300 medical representatives. Norgine is developing a pipeline of innovative pharmaceutical products addressing serious unmet medical needs with a focus on gastroenterology, hepatology and pain management. Additional information about Norgine can be found at [www.norgine.com](http://www.norgine.com).

- ends -

For further information, please contact :

Paul Pay  
Business Development Director  
Norgine International Limited  
Keaton House  
Widewater Place  
Moorhall Road  
Harefield  
Middx UB9 6NS  
UK  
Tel: +44 1895 453710  
E-mail: [ppay@norgine.com](mailto:ppay@norgine.com)

Date: May 2004